Marijeta Kralj graduated in molecular biology from the Faculty of Natural Sciences, University of Zagreb,Zagreb, Croatia in 1990. She received her Ph.D. degree in molecular and cell biology in 2001. From 2003 to 2008 she was the Head of Laboratory of Functional Genomics at the division of Molecular Medicine, Rudjer Boškovic Institute, Zagreb, Croatia . Now she serves as the Head of Laboratory of Experimental Therapy at the same Institute where is in charge of organizing and managing the antitumor screening platform for discovering novel anticancer compounds. Her research areas are tumor therapy, including gene therapy, with special emphasis on studying various cell death-responses to tumor therapy and search for novel potential antitumor compounds. Kralj worked as a coordinator of several scientific projects, or projects with SME. She has been a Shareholder of Institute Ruder Boskovic biotech spin-off company BioZyne Ltd, and a Member of its Senior Management Team. Kralj published over 80 scientific papers and is a coauthor on 5 patents and patent applications. Papers are citied over 770 times (H-index 17).And a reviewer for many respectable med-chem/pharmacology/oncology journals.
Biography Updated on 20 September 2012